Chemoprevention of colorectal cancer: Problems, progress, and prospects

Gastroenterology Clinics of North America

Volumn 31, Issue 4, 2002, Pages 971-999

  Viner, Jaye L ^a   Umar, Asad ^a   Hawk, Ernest T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; BALSALAZIDE; CALCIUM; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; EFLORNITHINE; FLUOROURACIL; FLURBIPROFEN; FOLIC ACID; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NIMESULIDE; ORENGEDOKU TO; PHENOL DERIVATIVE; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; RESISTANT STARCH; ROFECOXIB; SELENIUM; STARCH; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN; VITAMIN D;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MODEL; CANCER PREVENTION; CARCINOGENESIS; CLINICAL RESEARCH; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DIET; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFECT; DRUG TARGETING; HIGH RISK POPULATION; HUMAN; IN VIVO STUDY; METHODOLOGY; NONHUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; VITAMIN SUPPLEMENTATION;

CHEMOPREVENTION; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN; RISK FACTORS;

EID: 0036896978     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(02)00055-9     Document Type: Review

References (97)

1. Fearon ER. A genetic basis for the multi-step pathway of colorectal tumorigenesis. Princess Takamatsu Symp 1991;22:37-48.
2. Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer. Science 1997;278:1043-50.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Tejpar S, Cassiman JJ, Van Cutsem E. The molecular basis of colorectal cancer. Acta Gastroenterol Belg 2001;64:249-54.
5. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
6. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: Results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32.
7. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study [published erratum appears in N Engl J Med 1993 Aug 26;329(9):672]. N Engl J Med 1993;328:1365-71.
8. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
9. Wattenberg LW. Potential inhibitors of colon carcinogenesis. Am J Dig Dis 1974;19:947-53.
10. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
11. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7.
12. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997;94:10367-72.
13. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
14. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658-62.
15. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
16. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8.
17. Wallace K, Baron JA, Cole BF, et al. Calcium carbonate chemoprevention in the large bowel: Effects on hyperplastic polyps, tubular adenomas, and more advanced lesions. Proc AACR 2002;43:163-4.
18. Narisawa T, Kohno KI, Yamaguchi T, et al. Chemoprevention of development of colonic adenomatosis and carcinomatosis with intrarectal dose of 5-FU on animal model. Cancer 1980;45:439-43.
19. Corpet DE, Tache S. Modulation of colon carcinogenesis. Review of experimental data (rats, mice). Nutr Cancer 2002, in press.
20. Umar A, Viner JL, Richmond E, et al. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 2002;7:2-26.
21. Bussey HJ, DeCosse JJ, Deschner EE, et al. A randomized trial of ascorbic acid in polyposis coli. Cancer 1982;50:1434-9.
22. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
23. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62.
24. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994;331:141-7.
25. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-55.
26. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
27. Sasai H, Masaki M, Wakitani K. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis 2000;21:953-8.
28. Williamson SL, Kartheuser A, Coaker J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 1999;20:805-10.
29. Edelmann W, Umar A, Yang K, et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 2000;60:803-7.
30. Edelmann W, Yang K, Umar A, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997;91:467-77.
31. Prolla TA, Baker SM, Harris AC, et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 1998;18:276-9.
32. Reitmair AH, Schmits R, Ewel A, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995;11:64-70.
33. Datto M, Wang XF. The Smads: Transcriptional regulation and mouse models. Cytokine Growth Factor Rev 2000;11:37-48.
34. Weinstein M, Yang X, Deng C. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 2000;11:49-58.
35. Lipkin M, Yang K, Edelmann W, et al. Preclinical mouse models for cancer chemoprevention studies. Ann N Y Acad Sci 1999;889:14-9.
36. Baron JA, Cole BF, Mott LA, et al. Aspirin chemoprevention of colorectal adenomas. Proc AACR 2002;43:669.
37. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
38. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
39. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
40. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
41. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
42. Choi SW, Mason JB. Folate and carcinogenesis: An integrated scheme. J Nutr 2000;130:129-32.
43. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84.
44. Reddy BS. Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. J Nutr 1999;129:1478S-82.
45. Roberfroid MB. Prebiotics and probiotics: are they functional foods?. Am J Clin Nutr 2000;71:1682S-7; discussion 1688S-90.
46. Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 2000;60:2304-12.
47. Lobell RB, Kohl NE. Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 1998;17:203-10.
48. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
49. Nakagawa K. Tyrosine kinase inhibitors-solid cancers. Gan To Kagaku Ryoho 2001;28: 608-13.
50. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
51. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9:823-33.
52. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
53. Cirielli C, Inyaku K, Capogrossi MC, et al. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 1999;43:99-108.
54. Heise CC, Williams AM, Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999;59:2623-8.
55. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43:S61-8.
56. Kelloff GJ, Johnson JR, Crowell JA, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1-10.
57. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 1995;87:1760-6.
58. Bonithon-Kopp C, Kronborg O, Giacosa A, et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000;356:1300-6.
59. Malila N, Virtamo J, Virtanen M, et al. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prev 1999;8:489-93,
60. Albanes D, Malila N, Taylor PR, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: Results from a controlled trial (Finland). Cancer Causes Control 2000;11:197-205.
61. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63. [published erratum appears in JAMA 1997 May 21;277(19):1520].
62. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
63. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
64. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
65. Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 2002;122:641-5.
66. Cats A, Kleibeuker JH, van der Meer R, et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 1995;87:598-603.
67. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;86:2551-63.
68. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.
69. Hawk E, Viner JL, Lawrence JA. Biomarkers as surrogates for cancer development. Curr Oncol Reports 2000;2:242-50.
70. Baron JA, Tosteson TD, Wargovich MJ, et al. Calcium supplementation and rectal mucosal proliferation: A randomized controlled trial. J Natl Cancer Inst 1995;87:1303-7.
71. Stern HS, Gregoire RC, Kashtan H, et al. Long-term effects of dietary calcium on risk markers for colon cancer in patients with familial polyposis. Surgery 1990;108:528-33.
72. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38:813-30.
73. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-8.
74. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
75. Winde G, Schmid KW, Brandt B, et al. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997;40:1156-68; discussion 1168-69.
76. Anderson WF, Umar A, Viner JL, et al. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002;8:1035-62.
77. Ruffin MT, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose. J Natl Cancer Inst 1997;89:1152-60.
78. Kelloff GJ, Boone CW, Crowell JA, et al. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem Suppl 1994;19:1-9.
79. Humar B, D'Orazio D, Albrecht C, et al. Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status. Int J Oncol 2001;19:1179-86.
80. Umar A, Viner JL, Hawk ET. The future of colon cancer prevention. Ann N Y Acad Sci 2001;952:88-108.
81. Gohagan JK, Prorok PC, Kramer BS, et al. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. Cancer 1995;75:1869-73.
82. Hao XP, Pretlow TG, Rao JS, et al. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001;61:8085-8.
83. Pretlow TP. Aberrant crypt foci and K-ras mutations: Earliest recognized players or innocent bystanders in colon carcinogenesis? Gastroenterology 1995;108:600-3.
84. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
85. Rostom A, Wells G, Tugwell P, et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000;27:2203-14.
86. Gupta RA, DubBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev 2001;1:11-21.
87. Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000;60:1864-70.
88. Li H, Schut HA, Conran P, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999;20:425-30.
89. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77:1309-13.
90. Rao CV, Tokumo K, Rigotty J, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51:4528-34.
91. Reddy BS, Nayini J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990;50:2562-8.
92. Smith RA, Cokkinides V, von E, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
93. Emilien G, Ponchon M, Caldas C, et al. Impact of genomics on drug discovery and clinical medicine. QJM 2000;93:391-423.
94. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9.
95. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
96. Labayle D, Boyer J, Drouhin F, et al. Sulindac in familial adenomatous polyposis. Lancet 1994;343:417-8.
97. Gaziano JM, Hennekens CH, Buring JE. Methodological issues in the design of primary prevention trials. IARC Sci Publ 1996;136:7-12.